Search

Your search keyword '"Hanna K. Sanoff"' showing total 210 results

Search Constraints

Start Over You searched for: Author "Hanna K. Sanoff" Remove constraint Author: "Hanna K. Sanoff"
210 results on '"Hanna K. Sanoff"'

Search Results

1. Scoping review of values elicitation tools for treatment decisions in hepatocellular carcinoma

2. A phase I evaluation of the effect of curcumin on dose‐limiting toxicity and pharmacokinetics of irinotecan in participants with solid tumors

3. Qualitative evaluation of barriers and facilitators to hepatocellular carcinoma care in North Carolina

4. Patterns of Sociodemographic and Clinicopathologic Characteristics of Stages II and III Colorectal Cancer Patients by Age: Examining Potential Mechanisms of Young-Onset Disease

5. Hepatocellular Carcinoma Surveillance among Individuals with Cirrhosis: Trends by Payer, Etiology, and Calendar Year, from a Statewide, Multi-Payer Dataset, 2010–2018

6. Supplementary Table 8 from Hepatocellular Carcinoma Surveillance among Individuals with Cirrhosis: Trends by Payer, Etiology, and Calendar Year, from a Statewide, Multi-Payer Dataset, 2010–2018

7. Supplementary Table 12 from Hepatocellular Carcinoma Surveillance among Individuals with Cirrhosis: Trends by Payer, Etiology, and Calendar Year, from a Statewide, Multi-Payer Dataset, 2010–2018

8. Supplementary Table 7 from Hepatocellular Carcinoma Surveillance among Individuals with Cirrhosis: Trends by Payer, Etiology, and Calendar Year, from a Statewide, Multi-Payer Dataset, 2010–2018

9. Supplementary Methods from Hepatocellular Carcinoma Surveillance among Individuals with Cirrhosis: Trends by Payer, Etiology, and Calendar Year, from a Statewide, Multi-Payer Dataset, 2010–2018

10. Supplementary Table 5 from Hepatocellular Carcinoma Surveillance among Individuals with Cirrhosis: Trends by Payer, Etiology, and Calendar Year, from a Statewide, Multi-Payer Dataset, 2010–2018

11. Supplementary Table 9 from Hepatocellular Carcinoma Surveillance among Individuals with Cirrhosis: Trends by Payer, Etiology, and Calendar Year, from a Statewide, Multi-Payer Dataset, 2010–2018

12. Supplementary Table 6 from Hepatocellular Carcinoma Surveillance among Individuals with Cirrhosis: Trends by Payer, Etiology, and Calendar Year, from a Statewide, Multi-Payer Dataset, 2010–2018

13. Data from Hepatocellular Carcinoma Surveillance among Individuals with Cirrhosis: Trends by Payer, Etiology, and Calendar Year, from a Statewide, Multi-Payer Dataset, 2010–2018

14. Supplementary Table 4 from Hepatocellular Carcinoma Surveillance among Individuals with Cirrhosis: Trends by Payer, Etiology, and Calendar Year, from a Statewide, Multi-Payer Dataset, 2010–2018

15. Supplementary Table 3 from Hepatocellular Carcinoma Surveillance among Individuals with Cirrhosis: Trends by Payer, Etiology, and Calendar Year, from a Statewide, Multi-Payer Dataset, 2010–2018

18. Data from Prognostic and Predictive Biomarkers in Patients with Metastatic Colorectal Cancer Receiving Regorafenib

19. Figure S1, Table S1, Table S2, Table S3, Table S4, Table S5, Table S6 from Prognostic and Predictive Biomarkers in Patients with Metastatic Colorectal Cancer Receiving Regorafenib

20. Impact of the Cancer and Aging Research Group score and treatment intensity on survival and toxicity outcomes in older adults with advanced noncolorectal gastrointestinal cancers

21. Predictive Modeling for Adverse Events and Risk Stratification Programs for People Receiving Cancer Treatment

22. Trimodality Therapy vs Definitive Chemoradiation in Older Adults With Locally Advanced Esophageal Cancer

23. Phase II Single-Arm Study of Palbociclib and Cetuximab Rechallenge in Patients with KRAS/NRAS/BRAF Wild-Type Colorectal Cancer

24. Medicare/Medicaid Insurance, Rurality, and Black Race Associated With Provision of Hepatocellular Carcinoma Treatment and Survival

25. KDR genetic predictor of toxicities induced by sorafenib and regorafenib

26. Effectiveness of adjuvant <scp>FOLFOX</scp> vs <scp>5FU</scp> / <scp>LV</scp> in adults over age 65 with stage <scp>II</scp> and <scp>III</scp> colon cancer using a novel hybrid approach

27. Prognostic and Predictive Biomarkers in Patients with Metastatic Colorectal Cancer Receiving Regorafenib

28. Combination Antiangiogenic and Immunotherapy for Advanced Hepatocellular Carcinoma: Evidence to Date

29. Patient-Oncologist Communication Regarding Oral Chemotherapy During Routine Office Visits

30. A multi‐institutional phase 2 trial of regorafenib in refractory advanced biliary tract cancer

31. Antibacterial Use Is Associated with an Increased Risk of Hematologic and Gastrointestinal Adverse Events in Patients Treated with Gemcitabine for Stage IV Pancreatic Cancer

32. Association between Concomitant Use of Hydrochlorothiazide and Adverse Chemotherapy-Related Events among Older Women with Breast Cancer Treated with Cyclophosphamide

33. Associations Between Unprocessed Red Meat and Processed Meat With Risk of Recurrence and Mortality in Patients With Stage III Colon Cancer

34. Molecular and Clinical Characterization of a Claudin-Low Subtype of Gastric Cancer

35. Patterns of care amongst older adults diagnosed with locally advanced esophageal cancer: A cohort study

36. Improving Treatment Approaches for Rectal Cancer

37. Phase I/II trial of nano-camptothecin CRLX101 with capecitabine and radiotherapy as neoadjuvant treatment for locally advanced rectal cancer

38. Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome

39. Geriatric Assessment Predicts Hospitalization Frequency and Long-Term Care Use in Older Adult Cancer Survivors

40. Inflammatory markers and overall survival in older adults with cancer

41. Cancer of unknown primary

42. All You Need to Know About DPYD Genetic Testing for Patients Treated With Fluorouracil and Capecitabine: A Practitioner-Friendly Guide

43. Stereotactic Body Radiation Therapy for Recurrent, Isolated Hepatocellular Carcinoma Lymph Node Metastasis With or Without Prior Liver Transplantation

44. DISPARITIES AND HEALTH EQUITY: Racial Differences in Patterns of Health Care Access in a Cohort of Cancer Survivors: A Latent Profile Analysis Approach

45. Managing Grief, Loss, and Connection in Oncology-What COVID-19 Has Taken

46. Telemedicine for Cancer Care in the Time of COVID-19

47. Effectiveness of adjuvant FOLFOX vs 5FU/LV in adults over age 65 with stage II and III colon cancer using a novel hybrid approach

48. Oncology pharmacist-led medication reconciliation among cancer patients initiating chemotherapy

49. Multicenter, randomized, double‐blind phase 2 trial of <scp>FOLFIRI</scp> with regorafenib or placebo as second‐line therapy for metastatic colorectal cancer

50. Frailty and skeletal muscle in older adults with cancer

Catalog

Books, media, physical & digital resources